Skip to content
MedGadget – Medical Technology and Healthcare News Website Logo

MedGadget

Where Medicine Meets Technology

  • Author
  • Contact Us
  • About Us
Top Stories
Vetter Expands Commercial Fill-and-Finish Capacity with Ten New Manufacturing Lines
Vetter Expands Commercial Fill-and-Finish Capacity with Ten New Manufacturing Lines
Bristol Myers Squibb Q3 2026 results graphic about pipeline data
Posted inPharmaceutical

Bristol Myers Squibb Q3 2026 Results: What the Pipeline Data on CELMoDs and Admilparant Show

The Bristol Myers Squibb Q3 2026 results include CELMoD, admilparant and RYZ101 updates. What each result shows and what is pending.
Continue Reading
October 30, 2026
Laurus Labs Galenvs acquisition graphic about oligonucleotide technology
Posted inBio Technology

Laurus Labs Galenvs Acquisition: The Oligonucleotide and Nanoparticle Technology Behind the Deal

The Laurus Labs Galenvs acquisition buys oligonucleotide and nanoparticle skills. What the technology involves and what is not shown.
Continue Reading
October 30, 2026
Fortis Healthcare acquisition graphic about care quality in Bengaluru
Posted inHealthcare Services

Fortis Healthcare Acquisition of Suguna Hospital: What Consolidation Means for Care Quality in Bengaluru

The Fortis Healthcare acquisition adds 110 beds in north-west Bengaluru. What evidence says about hospital deals and quality.
Continue Reading
October 30, 2026
Top Categories
Healthcare IT
Healthcare IT
Medical Device
Medical Device
Pharmaceutical
Pharmaceutical
Graphic: OncoSil pancreatic cancer clinical trial, a tumour circle filled with microparticle dots beside 120 patients, five centres and single versus repeat implants
Posted inMedical Device

European PULSE Trial to Test Repeat OncoSil Implants in Pancreatic Cancer

OncoSil joins the EU-backed PALACROS programme via the PULSE Phase 2 trial: 120 patients, five centres, single versus repeat implants. No results yet.
October 13, 2026
Opamtistomig Fast Track: three-stage chevron graphic from Phase I/IIa to Phase II to ESMO data
Posted inPharmaceutical

FDA Grants Fast Track Status to Leads Biolabs’ Opamtistomig in Biliary Tract Cancer

Opamtistomig Fast Track: FDA status for first-line biliary tract cancer, nine days after submission. What it means, the data so far and what ESMO may show.
October 13, 2026
Encaleret ADH1 Phase 3: dumbbell graphic comparing symptom improvement rates on encaleret versus standard of care
Posted inPharmaceutical

Encaleret Improves Symptoms and Bone Turnover in Phase 3 ADH1 Study

Encaleret ADH1 Phase 3: PTH recovered in 91% and more patients reported symptom gains, but group sizes, statistics and safety data were not disclosed.
October 13, 2026
Tovinontrine HFrEF Phase 2: dose tiles showing greatest NT-proBNP reduction at 2.5 mg and no benefit at 50 mg
Posted inPharmaceutical

Cardurion Reports Positive Phase 2 Results for Tovinontrine in HFrEF

Tovinontrine HFrEF Phase 2: lower doses cut NT-proBNP in 529 patients, but 50 mg did not, and HFpEF showed no change. What is proven and what is not.
October 13, 2026
ICP-B161 IND approval: Y-shaped bispecific antibody graphic binding TL1A and IL-23p19
Posted inPharmaceutical

InnoCare Wins China IND Approval for IBD Bispecific Antibody ICP-B161

ICP-B161 IND approval: China clears InnoCare’s TL1A and IL-23p19 bispecific antibody for trials in IBD. What the company claims and what is undisclosed.
October 13, 2026
CAMCEVI NMPA approval: timeline graphic showing six months between injections of the leuprolide depot
Posted inPharmaceutical

Foresee’s CAMCEVI Wins NMPA Approval in Advanced Prostate Cancer

CAMCEVI NMPA approval: China clears Foresee’s six-month leuprolide depot for advanced prostate cancer; GenSci to sell it. What is and is not known.
October 13, 2026
Grünenthal Asia-Pacific pain access: hub graphic linking DKSH to eight Asia-Pacific markets and a South Korea licence
Posted inPharmaceutical

Grünenthal Widens Asia-Pacific Pain Access Through DKSH and Korea Deals

Grünenthal Asia-Pacific pain access plan: DKSH to seek approvals for four medicines in eight markets, plus a Qutenza licence in South Korea. What is known.
October 13, 2026
Everest Medicines mRNA team: Lakshmi Srinivasan and Brandon Coder join, with cancer vaccine candidates EVM14 and EVM16
Posted inBio Technology

Everest Medicines Strengthens mRNA Team with Two Former Moderna Executives

Everest Medicines mRNA team adds two former Moderna scientists to lead translational work on its cancer vaccines EVM14 and EVM16.
October 12, 2026
SYCUME inactive thyroid eye disease: 60.4% responders versus 23.5% on placebo at week 24
Posted inPharmaceutical

Innovent Reports Phase 3 Success for SYCUME in Inactive Thyroid Eye Disease

SYCUME inactive thyroid eye disease: Innovent reports Phase 3 success, with 60.4% responders vs 23.5% on placebo at week 24 in RESTORE-3.
October 12, 2026
Deucrictibant HAE Phase 3: symptom relief at 1.28 hours and resolution at 11.95 hours on a 12-hour axis
Posted inPharmaceutical

Deucrictibant Shows Faster Symptom Relief in Phase 3 HAE Study, Published in The Lancet

Deucrictibant HAE Phase 3 RAPIDe-3 results in The Lancet: oral capsule showed symptom relief in 1.28 hours. FDA decision due April 2027.
October 12, 2026

Posts pagination

Previous page 1 … 9 10 11 12 13 … 25 Next page

All Categories

  • Bio Technology
  • Healthcare IT
  • Healthcare Services
  • Life Science
  • Medical Device
  • Pharmaceutical
  • Press Releases
  • Uncategorized
Press Releases
Vetter Expands Commercial Fill-and-Finish Capacity with Ten New Manufacturing Lines
Posted inPress Releases

Vetter Expands Commercial Fill-and-Finish Capacity with Ten New Manufacturing Lines

Firefly Neuroscience and NeuroSigma Expand Access to Non-Drug Pediatric ADHD Treatment
Posted inPress Releases

Firefly Neuroscience and NeuroSigma Expand Access to Non-Drug Pediatric ADHD Treatment

InSilicoTrials Joins ARPA-H CIRCLE Program to Advance Digital Health Through Critical Care Digital Twins
Posted inPress Releases

InSilicoTrials Joins ARPA-H CIRCLE Program to Advance Digital Health Through Critical Care Digital Twins

Grünenthal and DKSH Expand Pain Medicine Partnership Across Eight Asia-Pacific Markets
Posted inPress Releases

Grünenthal and DKSH Expand Pain Medicine Partnership Across Eight Asia-Pacific Markets

Copyright 2026 — MedGadget.
Scroll to Top